Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.

Leukemia - 1 Mar 2020

Kamijo Hiroaki, Miyagaki Tomomitsu, Takahashi-Shishido Naomi, Nakajima Rina, Oka Tomonori, Suga Hiraku, Sugaya Makoto, Sato Shinichi

Abstract excerpt

CD47 is highly expressed on various hematopoietic malignancies, and enables cancer cells to avoid immunosurveillance. Its ligand, thromobospondin-1 (TSP-1) is a multifunctional protein, and CD47/TSP-1 interactions promote tumor progression in various malignancies. In this study, we investigated roles of TSP-1 and CD47 in cutaneous T-cell lymphoma (CTCL). Flow cytometric analysis and immunohistochemistry showed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to Cell Movement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Disease Progression

Share to Immunohistochemistry

Share to Lymphoma, T-Cell, Cutaneous

Share to Phosphorylation

Share to Thrombospondin 1

Source

Identifiers

PMID: 31712778
DOI: 10.1038/s41375-019-0622-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.PMID 31712778Read ↗

Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathwaysSemantic proximity Read ↗

Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatmentSemantic proximity Read ↗

Thrombospondin-1 and cutaneous melanoma.Semantic proximity Read ↗

Role of CD47 in tumor immunity: a potential target for combination therapySemantic proximity Read ↗

Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.Semantic proximity Read ↗

Preclinical in vitro and in vivo evidence for targeting CD74 as an effective treatment strategy for cutaneous T-cell lymphomasSemantic proximity Read ↗

Tspan protein family: focusing on the occurrence, progression, and treatment of cancerSemantic proximity Read ↗

Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell LymphomaSemantic proximity Read ↗

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.Semantic proximity Read ↗

Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasisSemantic proximity Read ↗

Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphomaSemantic proximity Read ↗

Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.